Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults

Clin Infect Dis. 2002 Jul 15;35(2):130-9. doi: 10.1086/341024. Epub 2002 Jun 24.

Abstract

We performed a clinical study of pneumococcal endocarditis (PE) in adults at 15 major Spanish hospitals during a 21-year period (1978-1998). During this time, 63 patients had PE due to Streptococcus pneumoniae diagnosed. Of the 63 isolates recovered from these patients, 24 (38%) and 6 (10%) showed resistance to penicillin (minimum inhibitory concentration [MIC], 0.1-4 microg/mL) and cefotaxime (MIC, 1 microg/mL), respectively. Twenty-two (35%) of the patients died. Left-side heart failure, but not penicillin resistance, was independently associated with a higher risk of death (odds ratio, 1.33; 95% confidence interval, 1.04-1.71; P=.026). Patients without meningitis who had PE due to penicillin-resistant S. pneumoniae could be treated with high-dose penicillin or a third-generation cephalosporin if the MIC for penicillin was < or =1 microg/mL. For patients with concurrent meningitis, high doses of cefotaxime could be used if the MIC for cefotaxime was < or =1 microg/mL. Early recognition of heart failure and surgery may help to decrease mortality.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Cefotaxime / administration & dosage
  • Cefotaxime / metabolism
  • Cefotaxime / therapeutic use
  • Cephalosporins / administration & dosage
  • Cephalosporins / metabolism
  • Cephalosporins / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Endocarditis, Bacterial / complications
  • Endocarditis, Bacterial / diagnosis*
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / epidemiology
  • Female
  • Heart Failure / etiology
  • Heart Failure / mortality
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Penicillin Resistance*
  • Penicillins / administration & dosage
  • Penicillins / metabolism*
  • Penicillins / therapeutic use
  • Pneumococcal Infections / complications
  • Pneumococcal Infections / diagnosis*
  • Pneumococcal Infections / drug therapy*
  • Pneumococcal Infections / epidemiology
  • Prognosis
  • Prospective Studies
  • Spain / epidemiology
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / isolation & purification*
  • Treatment Outcome
  • Ventricular Dysfunction, Left / complications
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / surgery

Substances

  • Cephalosporins
  • Penicillins
  • Cefotaxime